Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024Marine Maurel, Ana Paula Rodrigues, Iván Martínez‐Baz et al.|Eurosurveillance|2024Cited by 50
Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre studyEsther Kissling, Francisco Pozo, Iván Martínez‐Baz et al.|Influenza and Other Respiratory Viruses|2022Cited by 45
Influenza vaccine effectiveness in Europe: Results from the 2022–2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre studyMarine Maurel, Francisco Pozo, Gloria Pérez‐Gimeno et al.|Influenza and Other Respiratory Viruses|2024Cited by 28
Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023–January 2024Charlotte Lanièce Delaunay, Esther Kissling, Aryse Melo et al.|Vaccine|2024Cited by 24
Überwachung von COVID-19 durch Erweiterung der etablierten Surveillance für AtemwegsinfektionenLuise Goerlitz, Silke Buda, Kristin Tolksdorf et al.|Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz|2021Cited by 13